Mazanowska O, Boratyńska M, Mróz E, Starek J
Katedry i Kliniki Nefrologii AM, Wrocławiu.
Pol Tyg Lek. 1994;49(6-7):154-7.
Norfloxacin (Nolicin Krka) has been administered to 22 patients with urinary tract infections. The drug has been administered in daily dose of 800 mg for 10 days. An ultimate result has been evaluated after 3 months. Sterile urine cultures or less that 10,000 cells per millilitre have been achieved in 13 (59%) patients. Relapse of infection with other strain have been found in 9 (41%) patients. No adverse reactions which required cessation of therapy have been noted. An examination of isolates sensitivity to norfloxacin in vitro has shown that the drug is active against Gram-negative Enterobacteriaceae, P. aeruginosa, and Gram-positive staphylococci. Various strains of streptococci have been insensitive to norfloxacin. The obtained results suggest that norfloxacin is useful antibacterial agent and produces both clinical and bacteriological improvement in about 60% of patients with urinary tract infections.
已对22例尿路感染患者使用诺氟沙星(诺立辛,克尔卡公司生产)。给药剂量为每日800毫克,疗程10天。3个月后评估最终结果。13例(59%)患者实现了无菌尿培养或每毫升细菌数少于10000个。9例(41%)患者出现了其他菌株引起的感染复发。未观察到需要停药的不良反应。对分离菌株进行的诺氟沙星体外敏感性检测表明,该药物对革兰氏阴性肠杆菌科细菌、铜绿假单胞菌和革兰氏阳性葡萄球菌有活性。各种链球菌菌株对诺氟沙星不敏感。所得结果表明,诺氟沙星是一种有效的抗菌剂,约60%的尿路感染患者在临床和细菌学方面均有改善。